Midland States Bancorp, Inc. reported a net income of $20.6 million for Q3 2026, or $0.95 per diluted share, up from $17.7 million in Q2. The bank saw loan growth of $39.1 million, driven by a 2.8% annualized increase in its Community Bank portfolio, and improved credit quality with lower nonperforming assets and moderated net charge-offs. Net interest margin rose to 4.03%, supported by an interest recovery on a nonaccrual loan. The company remains focused on profitable growth, credit normalization, and disciplined capital deployment to enhance shareholder value.
Midland States Bancorp, Inc. reported a net income of $20.6 million for Q3 2026, providing context for readers following financial sector developments. For readers following Financials-sector US stocks on Pluang, here is the market snapshot as of Oct 23, 2026 03:11 WIB: out of 142 priced stocks, 81 rose and 59 fell. Notable movers include RIOT at USD 12.87 with a 1-day change of -8.20% and Pluang order activity of 23% Sell / 77% Buy, NDAQ at USD 103.07 with a 1-day change of +7.23% and Pluang order activity of 93% Sell / 7% Buy, and CLSK at USD 8.12 with a 1-day change of -7.20% and Pluang order activity of 10% Sell / 90% Buy.
Remittix has raised $33 million in its presale, nearing its $36 million hard cap ahead of its November 24, 2026 launch. The project offers a PayFi ecosystem connecting crypto with bank payments, with active product use and testing underway. Meanwhile...
Share-ify introduced the S.A.F.E. Score™, an AI-powered forecasting engine designed to enhance supplier risk intelligence within its food safety and compliance solutions. This tool analyzes diverse data such as audit results, recall history, and insp...
EquipmentShare, a major U.S. construction equipment rental and technology provider, will announce its fiscal third quarter 2026 financial results after market close on November 9, 2026. The company will host a conference call for investors and analys...
Atlantic American Corporation received a Nasdaq Staff Delisting Determination due to missing its 2025 annual and 2026 quarterly SEC reports by the extended October 12 deadline. The company has since filed the 2025 annual report and is working to subm...
Lycia Therapeutics, a biotech company developing therapies targeting disease-causing proteins, priced its upsized initial public offering at $18 per share, raising approximately $317.5 million before expenses. The company plans to use the funds to ad...
